Can these growth shares provide high total returns?

Do these stocks offer an enticing mix of growth and value?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Finding companies which offer a mix of growth and value is an ever-present challenge for investors. Stocks which have downbeat outlooks may appear to be cheap, but they may also lack a clear catalyst to push their share price higher. Equally, high-growth stocks may lack a margin of safety as investor demand is likely to have pushed their valuations ever higher.

With this in mind, here are two shares which could be worth a closer look. Both of them have improving outlooks, and could offer value appeal for the long term.

Growth potential

Reporting on Tuesday was international aesthetics company Sinclair Pharma (LSE: SPH). The company released a trading update for the first half of the year. It showed further progress is being made as per the company’s strategy, with sales rising by 16.3% versus the same period of the prior year.

Looking ahead to the second half of the year, the company has noted several potential catalysts which could lead to an improving top line. For example, order phasing, the seasonality of sales in Brazil and strong anticipated US growth could all boost the company’s financial performance. The FDA label change for Silhouette Instalift is also positive news for the company and should make training simpler and cheaper. Meanwhile, the acquisition of the Refine system should also improve the growth outlook for the overall business.

Despite Sinclair Pharma being a lossmaking business at the present time, it is expected to report a black bottom line next year. This could prove to investors that its strategy is bearing fruit and may lead to a higher valuation. Beyond next year, the company appears to have a grip on its costs and alongside strong revenue growth this could lead to rising profitability over the long run.

Consistent performer

Also offering growth potential for the long term is sector peer Alliance Pharma (LSE: APH). The company has a wide range of products which have historically provided a very consistent revenue stream and rising profitability over recent years. This means that the stock is relatively reliable and stable, which could make it popular if the wider market experiences a negative period following the bull run of recent months.

Looking ahead, Alliance Pharma is expected to report a rise in its earnings of 5% this year and 11% next year. This puts it on a price-to-earnings growth (PEG) ratio of just 1.1, which suggests that it offers a wide margin of safety.

As well as this, it has strong income potential. Dividends are currently covered 3.1 times by profit and this suggests they could move higher at a brisk pace. With a dividend yield of 2.5%, Alliance Pharma could be a sound income play for the long run. With inflation moving higher, this could make it a worthwhile growth, value and income play.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of Alliance Pharma. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Shot of a young Black woman doing some paperwork in a modern office
Investing Articles

With an 8% dividend yield, I think this undervalued FTSE stock is a no-brainer buy

With an impressive yield and good track record of payments, Mark David Hartley is considering adding this promising FTSE share…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

£9,500 in savings? Here’s how I’d try to turn that into £1,809 a month of passive income

Investing a relatively small amount into high-yielding stocks and reinvesting the dividends paid can generate significant passive income over time.

Read more »

Businesswoman analyses profitability of working company with digital virtual screen
Investing Articles

Dividend star Legal & General’s share price is still marked down, so should I buy more?

Legal & General’s share price looks very undervalued against its peers. But it pays an 8%+ dividend yield, and has…

Read more »

Investing Articles

Dividend shares: 1 FTSE 100 stock to consider buying for chunky shareholder income

This company’s ‘clean’ dividend record looks attractive to me and I’d consider buying some of the shares to hold long…

Read more »

Investing Articles

3 of my top FTSE 250 stocks to consider buying before April

Buying undervalued UK shares can be a great way to generate long-term wealth. Here, Royston Wild reveals a handful on…

Read more »

Ice cube tray filled with ice cubes and three loose ice cubes against dark wood.
Investing Articles

Just released: our 3 top income-focused stocks to buy before April [PREMIUM PICKS]

Our goal here is to highlight some of our past recommendations that we think are of particular interest today, due…

Read more »

Investing Articles

Is this the best chance to buy cheap FTSE 100 shares in a generation?

I want to buy shares when they're cheap, and sell... never, just keep taking the dividends. And the FTSE 100…

Read more »

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

Could NatWest shares be 2024’s number one buy for passive income?

For those of us looking to earn some long-term passive income, how does NatWest's 7% dividend yield sound? It sounds…

Read more »